---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-099345"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2023-09-08T23:59:59+00:00"
generated_at: "2026-06-10T22:25:52.587558+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Regeneron CFO Landry to retire Feb 2024; Fenimore named successor; two new directors elected

## Summary
- Director Marc Tessier-Lavigne retired Sept 1, 2023 due to potential conflicts with other roles.
- CFO Robert E. Landry to retire in Feb 2024; Christopher Fenimore (SVP, Controller) to succeed him.
- Board elected Kathryn Guarini as Class III director and David Schenkein as Class II director effective Sept 8, 2023.
- Both new directors appointed to Audit (Guarini) and Technology (Schenkein) committees.
- No disagreements cited for Landry departure; new directors hold office until 2024 annual meeting.

## SEC filing metadata
- accession: 0001104659-23-099345
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2023-09-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/tm2325712d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-099345
- JSON: https://secwatch.observer/filing/0001104659-23-099345.json
- Plain text: https://secwatch.observer/filing/0001104659-23-099345.txt

## Key facts
- Executive change
  Marc Tessier-Lavigne retired as Director at REGENERON PHARMACEUTICALS, INC..
  - Action: retired
  - Role: Director
  source text: On September 1, 2023, Marc Tessier-Lavigne, Ph.D. notified Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) of his decision to retire, effective as of that date, as a director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm
- Executive change
  Robert E. Landry departed as Executive Vice President, Finance and Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..
  - Action: intends to retire
  - Role: Executive Vice President, Finance and Chief Financial Officer
  source text: On September 8, 2023, Robert E. Landry notified the Company of his intention to retire from his position as Executive Vice President, Finance and Chief Financial Officer of the Company in February 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm
- Executive change
  David P. Schenkein was elected as Class II Director at REGENERON PHARMACEUTICALS, INC..
  - Action: elected
  - Role: Class II Director
  source text: Regeneron’s board of directors (the “ Board ”) elected Kathryn Guarini, Ph.D. as a Class III director and David P. Schenkein, M.D. as a Class II director to fill the two vacancies on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm
- Executive change
  Kathryn Guarini was elected as Class III Director at REGENERON PHARMACEUTICALS, INC..
  - Action: elected
  - Role: Class III Director
  source text: Regeneron’s board of directors (the “ Board ”) elected Kathryn Guarini, Ph.D. as a Class III director and David P. Schenkein, M.D. as a Class II director to fill the two vacancies on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm
- Executive change
  Christopher Fenimore was appointed as Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: The Company intends to appoint Christopher Fenimore, currently the Company’s Senior Vice President, Controller, to succeed Mr. Landry as Chief Financial Officer of the Company effective upon Mr. Landry’s retirement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465923099345/0001104659-23-099345-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.